10th Neurodegenerative Drug Development Summit

With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.

From leveraging data from clinical samples to catalyze the next generation of therapies against Alzheimer’s and Parkinson’s disease, learning how to justify investment in rare neurodegenerative diseases, through to taking a multi-omic approach to target discovery, the 10th Neurodegenerative Drug Development Summit will siphon critical insights from Biogen, AbbVie, Roche, Takeda, Novartis and more to help you accelerate therapeutic development through to approval for NDD patients around the world.

Join us to witness this neuroscience renaissance head on and meet with the biggest neurodegenerative KOL’s across this exceedingly challenging and exciting field, as we fight to unravel the complexities of neurodegenerative drug development. Join 200+ neurodegenerative drug development experts to learn from those revolutionising this space into 2022 and beyond.

Tickets https://go.evvnt.com/961759-2?pid=5248
Brochure https://go.evvnt.com/961759-3?pid=5248

Speakers: Alejandro Rangel, Associate Professor of Medicine Universidad, Panamericana, Andrea Crotti, Principal Scientist - Early Discovery, Takeda, Beth Hoffman, Founder, President & Chief Executive Officer Origami, Therapeutics, Chris Winrow, Vice President & Head of Translational Medicine, Cyclerion, Daniel Alkon, President –Research, Synaptogenix, David Bearss, Chief Scientific, Officer, Halia Therapeutics, Dimitry Ofengeim, Head of Precision Neurology & Neuroinflammation, Sanofi, George Tetz, Chief Executive Officer, CLS Therapeutics & The Human Microbiology Institute, Gergely Toth, Chief Executive Officer & Chief Scientific Officer, Cantabio, Graham Dempsey, Chief Scientific, Officer, Q-State Bio, Habib Baghirov, Senior Scientific, Business Analyst, Roche, Jamil Beg, Life Science, Venture Capitalist, & Entrepreneur, 5am Ventures, Je Min Yoo, Chief Technology, Officer, Biographene, Johannes Krupp, Research Program Director for Neurology, Servier, John Gustofson, Managing Director, AbbVie, John Hey, Chief Scientific Officer, Alzheon, Jonathan Behr, Partner, Dementia Discovery Fund, Jonathan Proto, Principal Scientist, Sanofi, Judy Walker, Chief Medical, Officer, Cerecin, Katherine Deng, Principal Scientist, AbbVie, Keechan Ahn, Chief Scientific Officer, Astrogen, Lisa Shafer, Chief Scientific Officer, Cerebral Therapeutics, Magdalene Moran, President & Chief Scientific Officer, Carraway Therapeutics, Manuel Sanchez-Felix, Senior Fellow, Novel Delivery Technologies, Novartis, Marcy Taylor, Vice President of Research, Treventis, Martin Tolar, Founder, President & Chief Executive Officer, Alzheon, Melissa Geddie, Principal Scientist – Antibody Discovery, Biogen, Michela Gallagher, Founder & Chief Executive Officer, Agene Bio, Michele Vendruscolo, Professor, University of Cambridge, Murali Gopalakrishnan, Global Head of Neuroscience Search & Evaluation, AbbVie, Phllip Kong, Associate Director for Translational Medicine, Alector, Raj Ganesan, Senior Director -Protein Engineering & Antibody Discovery Research, Alector, Raphael Lis, Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory, Weill Cornell Medicine, Rob Shaffer, Founder, Enable Therapeutics, Ross Jeggo, Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria, Servier, Sharon Rosenzweig-Lipson, Vice President of Research & Development, AgeneBio, Stan Chamberlain, Chief Scientific Officer, T3D Therapeutics

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About